FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
Imagine being told you have prostate cancer and then learning that the treatment you are offered could leave you with life-changing side effects, even though you might not need it at all. That is the ...
Bob Lane emphasizes the importance of having a support system during prostate cancer diagnosis and treatment to help process information and provide emotional support. Lane's experience with cancer ...
Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...
Incontinence and other urinary problems after prostate cancer treatment can be eased with Kegel exercises, bladder training, ...
A large language model (LLM)-based multi-agent framework for risk stratification and treatment recommendations in localized prostate cancer (locPCa). This is an ASCO Meeting Abstract from the 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results